New targets for therapy of sarcoma

Current Opinion in Oncology

Volumn 20, Issue 4, 2008, Pages 400-406

  Magenau, John M ^a   Schuetze, Scott M ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Insulinlike growth factor 1 receptor; Mammalian target of rapamycin inhibitor; Sarcoma; Targeted therapy; Vascular endothelial growth factor receptor.

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; AMG 479; ANTHRACYCLINE; BEVACIZUMAB; CEDIRANIB; CETUXIMAB; CP 751871; DEFOROLIMUS; DOCETAXEL; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; GEMCITABINE; IFOSFAMIDE; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NVP AEW 541; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; R 1507; RAPAMYCIN; SCH 717454; SEMAXANIB; SOMATOMEDIN C RECEPTOR; SORAFENIB; STEM CELL FACTOR RECEPTOR; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ADVANCED CANCER; ANGIOSARCOMA; BREAST SARCOMA; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; DERMATOFIBROSARCOMA PROTUBERANS; DISEASE FREE SURVIVAL; DRUG EFFICACY; EWING SARCOMA; GASTROINTESTINAL STROMAL TUMOR; GLIOBLASTOMA; HUMAN; KAPOSI SARCOMA; KIDNEY CARCINOMA; KIDNEY SARCOMA; LEIOMYOSARCOMA; LIPOCYTIC SARCOMA; LYMPHOMA; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; METASTASIS; NEUROBLASTOMA; NONHUMAN; OSTEOSARCOMA; PERIPHERAL NERVE TUMOR; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SIGNAL TRANSDUCTION; SOFT TISSUE SARCOMA; SOLID TUMOR; SURVIVAL RATE; SYNOVIAL SARCOMA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; HUMANS; PROTEIN KINASE INHIBITORS; SARCOMA;

EID: 47249110359     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328303671d     Document Type: Review

References (62)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. Cancer J Clin 2007; 57:43-66.
2. Wunder J, Nielsen TO, Maki R, et al. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 2007; 8:513-524. An excellent comprehensive overview of past and future directions in sarcoma therapy.
3. Demetri G, Elias A. Results of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinic. Hematol Oncol Clin North Am 1995; 9:765-785.
4. Hartmann J. Systemic treatment options for patients with refractory adult-type sarcoma beyond anthracyclines. Anticancer Drugs 2007; 18:245-254. A comprehensive review exploring conventional, targeted, and experimental agents in treatment of advanced sarcoma.
5. Edmonson J, Ryan L, Blum R, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993; 11:1269-1275.
6. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995; 13:1537-1545.
7. Patel S, Vadhan-Raj S, Burgess M, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998; 21:317-321.
8. Maki R, Wathen J, Patel S, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research through Collaboration study 002. J Clin Oncol 2007; 25:2755-2763. Randomized study demonstrating superior progression-free and overall survival rates for patients treated with the combination compared to single-agent gemcitabine. The first study to demonstrate a survival advantage from combination chemotherapy in metastatic adult soft tissue sarcoma.
9. Helman L, Meltzer P. Mechanisms of sarcoma development. Nat Rev Cancer 2003; 3:685-694.
10. Smolewski P. Recent developments in the targeting of the mammalian target of rapamycin (mTOR) kinase pathway. Anticancer Drugs 2006; 17:487-549.
11. Wan X, Helman LJ. The biology behind mTOR inhibition in sarcoma. Oncologist 2007; 12:1007-1018. The above study provides an in depth review of the mTOR pathway and mechanisms of inhibition. Future directions in mTOR inhibition are also reviewed.
12. Shaw R, Bardeesy N, Manning B, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 2004; 6:91-99.
13. Hemant K, Bola F, Dahn L, et al. AKT proto-oncogene expression is an early event during sporadic colon carcinogenesis. Carcinogenesis 2002; 23:201-205.
14. Nanami I, Shuho S, Masafumi I, et al. Phosphorylation of Akt/PKB is required for suppression of cancer cell apoptosis and tumor progression in human colorectal carcinoma. Cancer 2002; 94:3127-3134.
15. Vivanco I, Sawyers C. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
16. Okuno S. Mammalian target of rapamycin inhibitors in sarcomas. Curr Opin Oncol 2006; 18:360-362.
17. Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007; 13:748-753. The above article describes an important role of the mTOR pathway in the development of leiomyosarcoma in a mouse model and suggests that inhibition of mTOR in this model has substantial antisarcoma activity.
18. Guba M, Von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8:128-135.
19. Mita MM, Mita AC, Tolcher AW, et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008; 26:361-367. A clinical study demonstrating inhibition of target pathway and preliminary activity for novel mTOR inhibitor in solid tumors.
20. Chawla SP, Tolcher AW, Staddon AP, et al. Updated results of a phase II trial of AP23573, a novel mTOR inhibitor, in patients with advanced soft tissue or bone sarcomas. J Clin Oncol 2006; 24:521s. (abstract 9505).
21. Okuno S, Mahoney M, Bailey H, et al. A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS). J Clin Oncol 2006; 24:521s. (abstract 9504).
22. Iwenofu OH, Lackman RD, Brooks JSJ, et al. Phosph-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted, mTOR, therapy. Mod Pathol 2007; 21:231-237. This study illustrates the potential for preselection to improve response rate of sarcomas to mTOR inhibitors, but findings need to be validated in prospective trials.
23. Sankhala KK, Shawla SP, Lagaru A, et al. Early response evaluation of therapy with AP23573 (an MTOR inhibitor) in sarcoma using (18F)2-fluoro-2deoxy-D-glucose (FDG) positron emission tomography (PET) scan. J Clin Oncol 2005; 23:823s. (abstract 9028).
24. Leary A, Johnston S. Small molecule signal transduction inhibitors for the treatment of solid tumors. Cancer Invest 2007; 25:347-365.
25. Corless C, Fletcher J, Heinrich M. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004; 22:3813-3825.
26. Demetri G, von Mehren M, Blanke C, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-480.
27. Merchant M, Woo C-W, Mackall C, Thiele C. Potential use of imatinib in Ewing's sarcoma: evidence for in vitro and in vivo activity. J Natl Cancer Inst 2002; 94:1673-1679.
28. Scotlandi K, Marnara M, Strammiello R, et al. C-KIT receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J Clin Oncol 2003; 21:1952-1960.
29. Hotfilder M, Lanvers C, Jurgens H, et al. C-KIT-expressing tumor cells are insensitive to imatinib mesylate. Cancer Chemother Pharmacol 2002; 50:167-169.
30. Bozzi F, Tamborini E, Negri T, et al. Evidence for activation of kit, PDFRα, and PDGFRβ receptors in the Ewing sarcoma family of tumors. Cancer 2007; 109:1638-1645.
31. Do I, Araujo E, Kalil R, et al. Protein expression of KIT and gene mutation of c-kit and PDGFRs in Ewing sarcoma. Pathol Res Pract 2007; 203:127-134. Molecular analysis of c-kit and pdgfr genes in 71 Ewing's samples demonstrating that activating mutations are in c-kit at a very low frequency and are not present in pdgfr.
32. Bond M, Berstein ML, Pappo A, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatr Blood Cancer 2008; 50:254-258. A controlled clinical trial demonstrating no significant activity of imatinib in Ewing's and other pediatric tumors.
33. Chugh R, Thomas D, Wathen P, et al. Imatinib mesylate in soft tissue and bone sarcomas: interim results of a Sarcoma Alliance for Research thru Collaboration (SARC) phase II trial. J Clin Oncol 2004; 22:818s. (abstract 9001). Maris J, Courtright J, Houghton P, et al. Initial testing of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2008; 50:581-587. Study describing the screening of small molecule VEGFR inhibitor in vitro and in xenograft model system against a panel of pediatric tumors.
34. Servent N, Maire G, Pedeutour F, et al. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer 2003; 37:1-19.
35. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002; 20:3586-3591.
36. McArthur GA, Demetri GD, Van Oosterom A, et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J Clin Oncol 2005; 23:866-873.
37. Chugh R, Maki RG, Baker LH, et al. A SARC phase II multicenter trial of imatinib mesylate (IM) in patients with aggressive fibromatosis. J Clin Oncol 2006; 24:523s. (abstract 9515).
38. Fayette J, Dufresne A, Blay JY, et al. Imatinib for the treatment of aggressive fibromatosis/desmoid tumors (AF/DT) failing local treatment: updated outcome and predictive factors for progression free survival. A FNCLCC French Sarcoma Group-GETO study. J Clin Oncol 2007; 25:560s. (abstract 10062).
39. Stacchiotti S, Ferrari S, Gronchi A, et al. Imatinib mesylate in advanced chordoma: a multicenter phase II study. J Clin Oncol 2007; 25:545s. (abstract 10003).
40. Lagonigro MS, Tamboini E, Negri T, et al. PDGFRα, PDGRFβ, and KIT expression/activation in conventional chondrosarcoma. J Pathol 2006; 208: 615-623.
41. Adams SF, Hickson JA, Yamad SD, et al. PDGFR-α as a potential therapeutic target in uterine sarcomas. Gynaecol Oncol 2007; 104:524-528.
42. Prayson RA, Yoder BJ, Barnett GH. Epidermal growth factor receptor is not amplified in schwannomas. Ann Diagn Pathol 2007; 11:326-329.
43. Li H, Velasco-Miguel S, Vass WC, et al. Epidermal growth factor signaling pathways are associated with tumorigenesis in the Nfl:p53 mouse tumor model. Cancer Res 2002; 62:4507-4513.
44. Albritton KH, Rankin C, Coffin CM, et al. Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). J Clin Oncol 2006; 24:524s. (abstract 9518).
45. Thomas D, Giordano TJ, Baker L, et al. Expression of receptor tyrosine kinases epidermal growth factor receptor and HER-2/neu in synovial sarcoma. Cancer 2005; 103:830-838.
46. Blay J, Le Cesne A, Whelan J, et al. Gefitinib in second line treatment of metastatic or locally advanced synovial sarcoma expressing HER1: a phase II trial of EORTC Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2006; 24:524s. (abstract 9517).
47. Folkman J. Angiogenesis. Annu Rev Med 2006; 57:1-18.
48. Shor A, Agresta S, Sondak V, et al. Therapeutic potential for directed tyrosine kinase inhibitor therapy in sarcomas. Cancer Control 2008; 15: 47-54. A concise well organized review of TKIs in sarcoma.
49. Dalal S, Berry A, Cullinane C, et al. Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing's sarcoma family. Clin Cancer Res 2005; 11:2364-2378.
50. Maris J, Courtright J, Houghton P, et al. Initial testing of the VEGFR inhibitor AZD2171 by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2008; 50:581-587. Study describing the screening of small molecule VEGFR inhibitor in vitro and in xenograft model system against a panel of pediatric tumors.
51. Heymach JV, Desai J, Demetri GD. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas. Clin Cancer Res 2004; 10:5732-5740.
52. D'Adamo D, Keohan M, Schuetze S, et al. Clinical results of a phase II study of sorafenib in patients (pts) with non-GIST sarcomas (CTEP study #7060). J Clin Oncol 2007; 25:545s. (abstract 10001).
53. Sleijfer S, Ray-Coquard I, Papai Z, et al. Pazopanib (GW786034) in patients with relapsed or refractory soft tissue sarcoma, a phase II study for the EORTC STBSG (EORTC 62043). CTOS 13th Annual Meeting 2007, 3 Nov 2007, Seattle, WA (abstract 875).
54. D'Ercole AJ. Actions of IGF system proteins from studies of transgenic and gene knockout models. In: Rosenfeld RD, Roberts CT, editors. The IFG system: molecular biology, physiology, and clinical applications. New Jersey: Humana press; 1999. pp. 545-574.
55. Hassan AB, Macaulay VM. The insulin growth factor system as a therapeutic target in colorectal cancer. Ann Oncol 2002; 13:349-356.
56. Cullen KJ, Yee D, Sly WS, et al. Insulin-like growth factory receptor expression and function in human breast cancer. Cancer Res 1990; 50:48-53.
57. Ge NL, Rudikoff S. Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood 2000; 96:2856-2861.
58. Kolb EA, Gorlick R, Houghton P, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the Pediatric Preclinical Testing Program. Pediatr Blood Cancer 2008; 50:1190-1197; doi:10.1002. Preclinical study demonstrating significant antitumor effect of humanized monoclonal antibody to IGF-1R in xenograft models of pediatric tumors.
59. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity and the insulinlike growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005; 65:3868-3876.
60. Haluska P, Shaw H, Batzel G, et al. Phase I dose escalation study of the antiinsulin-like growth factor-1 receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13:5834-5840.
61. Tolcher AW, Rothenberg ML, Rodon J, et al. A phase I pharmacokinetic and pharmacodynamic study of AMG 479, a fully human monoclonal antibody against insulin-like growth factor type 1 receptor (IGF-1R), in advanced solid tumors. J Clin Oncol 2007; 25:118s. (abstract 3002).
62. Benjamin R, Gore L, Dias C, et al. Activity of R1507, a fully humanized monoclonal antibody IGF-R (insulin-like growth factor receptor) antagonist, in patients with Ewing's sarcoma noted in a phase I study. CTOS 13th Annual Meeting 2007, 3 Nov 2007, Seattle, WA (abstract 932).